GlassScriptPhysician profile
Kinnari K Patel
NPI 1851341382
$5,987.09
in general payments reported to CMS, 2019-2025
25 companies · $776 in 2025
The $776 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,616 · 2020: $28.15 · 2021: $753 · 2022: $1,457 · 2023: $329 · 2024: $1,028 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,703.36 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $730.36 | 2019-2021 | |
| Shire North American Group INC | $721.36 | 2019 | |
| Sun Pharmaceutical Industries INC. | $569.52 | 2019-2025 | Cequa |
| Lumenis, INC | $500.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $232.00 | 2022-2025 | Eylea Hd |
| Oyster Point Pharma, INC. | $203.84 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $179.52 | 2019-2025 | Oxervate |
| Astellas Pharma US INC | $130.74 | 2024 | Izervay |
| Harrow Eye, LLC | $129.52 | 2024-2025 | Vevye |
| Abbvie INC. | $123.71 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $113.96 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $104.50 | 2022-2024 | |
| Alcon Vision LLC | $101.58 | 2019-2025 | Tryptyr, Eysuvis |
| Bausch & Lomb Americas INC. | $98.98 | 2023-2025 | Miebo, Xiidra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quidel Corporation | $89.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.76 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $54.44 | 2024 | Xdemvy |
| Sight Sciences, INC. | $25.79 | 2023 | Tearcare System |
| Ani Pharmaceuticals, INC. | $19.72 | 2025 | Purified Cortrophin Gel |
| Coopervision INC. | $16.33 | 2022 | |
| Amgen INC. | $16.17 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.92 | 2019 | |
| Allergan, INC. | $11.86 | 2020 | |
| Alimera Sciences, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinnari Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.